4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
Alzheimer's Association International Conference 2026
July 12-15, 2026 | London, United Kingdom, and Online
5938
The Oral P38a Kinase Inhibitor Neflamapimod Slows The Rate Of Clinical Worsening In Dementia With Lewy Bodies (DLB)
Poster Presenter
Authors
John-Paul Taylor, John Alam, Stephen N. Gomperts, Lawrence Honig, Niels Prins, Hui-May Chu, Amanda Gardner, Kelly Blackburn, Charlotte Teunissen, James Galvin
Affiliations
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA, Translational and Clinical Research Institute and NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle, United Kingdom, CervoMed, Inc., Boston, MA, USA, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, New York,NY, USA, Brain Research Centre, Amsterdam, Netherlands, Anoixis Corporation, Natick, MA, USA, Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA
Part of Topic
Video
In a 159-patient randomized trial in dementia with Lewy bodies, neflamapimod did not replicate phase 2a results in which it improved outcomes on CDR-SB versus placebo. In exploratory analyses of the current study, there was evidence that neflamapimod slowed worsening on CDR-SB in patients with low plasma p-tau181, and higher plasma drug concentrations; key lessons ahead of advancing into phase 3 development.
Comments
Email is required but is not shown publicly.
Loading comments...